Roche Bullish Despite Biosimilars Battering

Pharma Sales Down By 7% in Q4

 
• By Kevin Grogan

Its older oncology products are sinking but the Swiss major is confident about coming through COVID-19 in a strong position.

Roche_Logo_Glass
Tough Q4 for the Swiss major • Source: Archive

More from Earnings

More from Business